Research and Markets: Primary Biliary Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/0e3bdc/primary_biliary_ci) has announced the addition of GlobalData 's new report "Primary Biliary Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.

Primary Biliary Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global primary biliary cirrhosis therapeutics market. The report identifies the key trends shaping and driving the global primary biliary cirrhosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global primary biliary cirrhosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Primary Biliary Cirrhosis Therapeutics Market is Forecast to Show High Growth

GlobalData has estimated the global primary biliary cirrhosis therapeutics market to be valued at $264m in 2010. It is expected to grow to $445m with a Compound Annual Growth Rate (CAGR) of 7.8% by 2017. This growth is primarily attributed to the increasing prevalence of the disease due to the increasing awareness of the disease and early diagnosis. The diagnosis rate is also high in primary biliary cirrhosis (PBC). Around 60% of patients are asymptomatic at the time of diagnosis. Ursodiol of Axcan Pharma (Aptalis Pharma) is the only approved drug and the market is dominated by generics. Weak Pipeline will have No Impact during the Forecast Period

The authors analysis showed that there is only one molecule in the PBC pipeline. Since the pipeline is weak with no promising drugs to be launched in the forecast period the pipeline is not expected to have any impact on the market growth. INT-747 is the only molecule in the PBC pipeline. It is a farnesoid X receptor (FXR) agonist. INT-747 treatment prevents, and even reverses, liver damage caused by progressive fibrosis (scarring). Though the drug is a novel molecule and has disease-modifying properties it will not have an impact in the forecast period because it is in only in Phase II of development.

Current Treatment Options Create Low Unmet Need in the Market

GlobalData's analysis found that the unmet need in the PBC market is low, which implies that the market is well-served with the current product options. However, the market holds promise for new entrants to the PBC market. This is because while ursodiol improves the biochemical indices of the patients it doesn't reverse the disease. The response rate is also not high for ursodiol. It is more effective in the early stages than in the advanced stages. As a result the market needs new drugs with disease-modifying properties.

Key Topics Covered:

1 Table of contents

2 Primary Biliary Cirrhosis Therapeutics: Introduction

3 Primary Biliary Cirrhosis Therapeutics: Market Characterization

4 Primary Biliary Cirrhosis Therapeutics: Competitive Assessment

5 Primary Biliary Cirrhosis Therapeutics: Pipeline Assessment

6 Primary Biliary Cirrhosis Therapeutics: Clinical Trials Mapping

7 Primary Biliary Cirrhosis Therapeutics: Strategic Assessment

8 Primary Biliary Cirrhosis Therapeutics - Future Players

9 Primary Biliary Cirrhosis Therapeutics - Deals

10 Primary Biliary Cirrhosis Therapeutics - Appendix

Companies Mentioned: Intercept Pharmaceuticals, Inc. (Subsidiary of GENEXTRA S.p.A.)

For more information and to purchase this report, visit http://www.researchandmarkets.com/research/0e3bdc/primary_biliary_ci